These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28738101)

  • 1. Psychiatric symptoms associated with porphyria: A case report and brief review.
    Santos M; Madhusoodanan S; Kaur K; Brenner R
    Ann Clin Psychiatry; 2017 Aug; 29(3):203-204. PubMed ID: 28738101
    [No Abstract]   [Full Text] [Related]  

  • 2. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
    Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J
    Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma risperidone levels and clinical response in patients with first-episode psychosis.
    Verma SK; Tan CH; Chan YH; Chong SA
    J Clin Psychopharmacol; 2005 Dec; 25(6):609-11. PubMed ID: 16282849
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.
    Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I
    J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816
    [No Abstract]   [Full Text] [Related]  

  • 7. Paliperidone-Induced Hyponatremia.
    Tibrewal P; Dhillon R; Sharma J; Bastiampillai T
    Prim Care Companion CNS Disord; 2017 Jul; 19(4):. PubMed ID: 28767207
    [No Abstract]   [Full Text] [Related]  

  • 8. Atypical psychotic symptoms and Dandy-Walker variant.
    Williams AJ; Wang Z; Taylor SF
    Neurocase; 2016 Oct; 22(5):472-475. PubMed ID: 27662527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report.
    Yoshimura R; Hori H; Katsuki A; Atake K
    J UOEH; 2016 Sep; 38(3):233-6. PubMed ID: 27627971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Facial Dystonia (Meige or Brueghel Syndrome) Induced by Paliperidone Palmitate.
    Marques JG
    Prim Care Companion CNS Disord; 2017 Jan; 19(1):. PubMed ID: 28129491
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
    Fortea A; Ilzarbe D; Espinosa L; Solerdelcoll M; de Castro C; Oriolo G; Sugranyes G; Baeza I
    J Child Adolesc Psychopharmacol; 2018 May; 28(4):252-257. PubMed ID: 29381388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
    Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
    BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate: factors predicting continuation with treatment at 2 years.
    Taylor DM; Sparshatt A; O'Hagan M; Dzahini O
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):2011-2017. PubMed ID: 27743760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of psychotic schizophrenia spectrum disorders in adolescents].
    Popov YV; Yakovleva YA; Pisevich MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):47-50. PubMed ID: 26525621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solubilized delivery of paliperidone palmitate by D-alpha-tocopheryl polyethylene glycol 1000 succinate micelles for improved short-term psychotic management.
    Muthu MS; Sahu AK; Sonali ; Abdulla A; Kaklotar D; Rajesh CV; Singh S; Pandey BL
    Drug Deliv; 2016; 23(1):230-7. PubMed ID: 24853962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute psychosis in a polyglot: Linguistic regression to the mother tongue and restoration.
    Saito S
    Asian J Psychiatr; 2019 Jun; 43():91-92. PubMed ID: 31112897
    [No Abstract]   [Full Text] [Related]  

  • 17. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine and risperidone treatment of psychosis in Parkinson's disease.
    Ellis T; Cudkowicz ME; Sexton PM; Growdon JH
    J Neuropsychiatry Clin Neurosci; 2000; 12(3):364-9. PubMed ID: 10956570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.